Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual rosuvastatin crossover trial in coronary artery disease
ACTRN12616001544460Phase 3Recruiting
- Sponsor
- Dr Gregory Szto
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosuvastatin in coronary arteriosclerosis and hyperlipidemia (2 arms), sponsored by Dr Gregory Szto. Primary endpoints: Change in myalgia or muscle ache symptoms, Elevated muscle enzymes and 1 more. Started Nov 2016; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
coronary arteriosclerosishyperlipidemia
Beyond the preview
Go deeper on ACTRN12616001544460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001544460.